We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Market for qPCR Exceeds USD 3 Billion

By LabMedica International staff writers
Posted on 20 Nov 2014
The market for real-time quantitative polymerase chain reaction (qPCR) was valued at about USD 3.2 billion for 2013 according to Kalorama Information (New York, NY, USA) an increase from USD 2.8 billion in 2011. The healthcare market researcher said that the testing system is considered the workhorse of research providing high quality, reproducible data. It also has many clinical applications including viral detection and quantification, according to Kalorama’s new report. qPCR is considered the gold standard for accurate, sensitive, and fast quantification of nucleic acid sequences. qPCR has been established for a broad range of applications including genotyping, pathogen detection, DNA methylation analysis, and other functions.

PCR is used for testing for the presence of genetic disease mutations. Prospective parents can be tested for being genetic carriers, or their children tested for actually being affected by a disease. DNA samples for prenatal testing can be obtained by amniocentesis, chorionic villus sampling, or even by the analysis of rare fetal cells circulating in the mother's bloodstream. PCR analysis is also essential to preimplantation genetic diagnosis, where individual cells of a developing embryo are tested for mutations.

qPCR is increasingly being used in the medical diagnostic arena for diagnosis of bacterial disease, detection of antibiotic resistance, diagnosis of infectious disease, and quantification of bacterial load. It is also used to detect genetic abnormalities and cancer mutations.

“Many forms of cancer involve alterations to oncogenes,” said Mary Ann Crandall, Kalorama analyst and author of the report. “By using PCR-based tests to study these mutations, therapy regimens can sometimes be individually customized to a patient.”

qPCR-based diagnostic tests are expected to expand in the future. However, these tests will have to meet three requirements: adaptation of existing diagnostic tests, especially according to the discovery of new variants of target genes of specific pathogens, responsible for false-negative results; expansion of diagnostic applications; and lower cost. The benefit is early diagnosis of disease and rapid assessment of resistances to treatment.

The three recognized product types within the qPCR market include reagents, instruments, and software/services. The report, qPCR and dPCR Markets, breaks out the market into these segments, identifies application segments including clinical and research, and reviews companies participating in the market.

Kalorama Information, a division of MarketResearch dot com, supplies the latest in independent medical market research in diagnostics, biotech, pharmaceuticals, medical devices and healthcare; as well as a full range of custom research services.

Related Links:

Kalorama Information



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Xylazine Immunoassay Test
Xylazine ELISA

Latest Industry News

Thermo Fisher and Bio-Techne Enter Into Strategic Distribution Agreement for Europe

ECCMID Congress Name Changes to ESCMID Global

Bosch and Randox Partner to Make Strategic Investment in Vivalytic Analysis Platform